Scarica l'app Stockscreener
38.54
0.73%
0.28
Dopo l'orario di chiusura:
38.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HROW Giù?
Forum
Previsione
Frazionamento azionario
Harrow Inc Borsa (HROW) Ultime notizie
Andrew R. Boll named Harrow principal accounting officer as Randall E. Pollard departs - TradingView
Harrow, Inc. Announces Management Changes, Effective September 4, 2026 - marketscreener.com
Harrow Health Inc. (HROW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
HROW Q2 2026 Earnings: EPS Misses Estimates as Losses DeepenMid-Term Outlook - vinanet.vn
Harrow Inc stock gains as analysts see strong revenue growth ahead - AD HOC NEWS
Harrow Inc (HROW) Stock Up 5.6% and Still Undervalued -- GF Scor - GuruFocus
Harrow to Participate in Three Investor Conferences in September - Yahoo Finance
Harrow (HROW) Reported Positive IHEEZO Study Results In Intravitreal Injections - Sahm
Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move - vinanet.vn
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half - Sahm
Harrow (NASDAQ: HROW) CSO sells 11,250 shares in August option trade - Stock Titan
Harrow (HROW) Outlook: Ends Down by 2.64% at $40.95 for the Current Session; Next Session: Price Remains Between $38.90 Support and $43.00 Resistance on the DayShort Term Trading Ideas - vinanet.vn
What's Going On With Harrow Stock Friday?Harrow (NASDAQ:HROW) - Benzinga
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections - Sahm
BTIG Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $63 - moomoo.com
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target - Yahoo Finance
In a 50-patient study, Harrow’s eye gel was linked to about 58% less injection discomfort - Stock Titan
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $60 - moomoo.com
Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In? - simplywall.st
Harrow And 2 Other Growth Stocks Insiders Are Betting On - simplywall.st
Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com South Africa
Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com
Rice Hall James & Associates LLC Takes Position in Harrow, Inc. $HROW - MarketBeat
Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy? - simplywall.st
Harrow (HROW) Q2 2026 Earnings Call Transcript - The Globe and Mail
Harrow (NASDAQ:HROW) Insider Amir Shojaei Sells 11,250 Shares - MarketBeat
Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneLast Point Resistance - vinanet.vn
HROW Q2 2026 Earnings: Wider Loss of $0.34 per Share Misses Estimates by 85.19%, but Stock Rises 2.98 - vinanet.vn
Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold" - MarketBeat
HC Wainwright Issues Pessimistic Outlook for Harrow Earnings - marketbeat.com
Royce Micro-Cap Fund's Harrow Inc(HROW) Holding History - GuruFocus
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Harrow: The Q2 Turnaround Is Enough For A Cautious Buy (NASDAQ:HROW) - Seeking Alpha
HC Wainwright Forecasts Harrow's Q4 Earnings (NASDAQ:HROW) - MarketBeat
Harrow (NASDAQ:HROW) Stock Rating Lowered by Zacks Research - MarketBeat
Earnings Update: Harrow, Inc. (NASDAQ:HROW) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Harrow announces product updates - Nashville Post
Harrow, Inc. (HROW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition - Yahoo Finance
Q2 2026 Harrow Inc Earnings Call Transcript - GuruFocus
A Look at Harrow Inc (HROW) After 3.2% Decline -- GF Value $44.5 - GuruFocus
HROW Looks 10.8% Undervalued on GF Value™ as Market Prices Growt - GuruFocus
HROW Reiterated by BTIG -- Price Target Maintained at $63 - GuruFocus
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Dem - GuruFocus
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ... - Yahoo Finance
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - MarketBeat
Harrow Q2 2026 slides: strong demand growth amid profitability push By Investing.com - Investing.com Canada
Harrow Releases Q2 2026 Financial Results - AlphaStreet
Harrow Q2 Earnings Call Highlights - MarketBeat
Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - MarketBeat
Harrow Health, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Harrow, Inc. (HROW) Stock Analysis: A 66% Potential Upside Awaits Investors in the Eyecare Pharmaceutical Space - DirectorsTalk Interviews
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ... By GuruFocus - Investing.com Canada
HROW: Record Q2 2026 revenue and EBITDA growth, with expanded dry eye portfolio and robust pipeline - TradingView
How Profit-to-Loss Swing Despite Rising Sales At Harrow (HROW) Has Changed Its Investment Story - simplywall.st
HROW Looks 8.5% Undervalued on GF Value™ - GuruFocus
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Harrow affirms FY26 sales guidance of $350-365M vs $348.468M est - scanx.trade
HROW Looks 8.5% Undervalued on GF Value™ Amid Mixed Growth Signa - GuruFocus
Harrow, Inc. Announces $17.3 Million Net Loss in Q2 2026 Amid Revenue Growth - Kalkine Media
Harrow: Q2 Earnings Snapshot - marketscreener.com
Is Harrow Inc (HROW) Positioned for Growth After Q2 Earnings Rep - GuruFocus
Harrow (NASDAQ:HROW) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS - MarketBeat
1.66%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):